Resource impact statement
No significant resource impact is anticipated
We do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year (or £9,000 per 100,000 population).
This is because the technology is a further treatment option and has been commissioned by NHS England since 2015 for people with relapsing–remitting multiple sclerosis as a first-line treatment or as an alternative when other first-line treatments are not tolerated. Therefore, we do not think practice will change substantially as a result of this guidance.
Peginterferon beta‑1a involves less frequent injections than other beta interferons, so improves choice for people with relapsing–remitting multiple sclerosis.
This technology is commissioned by NHS England. Providers are NHS hospital trusts.
This page was last updated: